Ferdinand Verdonck, a veteran business leader, has joined Affimed Therapeutics AG as a member of the company’s supervisory board. He will also serve as chairman of the audit committee. Affimed is developing a portfolio of therapeutics based on bi-specific antibody technology.
Mr Verdonck is also chairman of the supervisory board of the gene therapy company uniQure NV, and is a director of Virtus Funds, JP Morgan European Investment Trust, Groupe SNEF and Laco Information Services. He holds a law degree from KU Leuven and degrees in economics from KU Leuven and the University of Chicago.
Affimed announced the appointment on 25 July 2014.
Copyright 2014 Evernow Publishing Ltd